Preoperative albuminuria (ACR ≥30 mg/dL) was independently
associated with WRF at 6 months after TAVR. Furthermore, patients
with an ACR ≥30 mg/dL had a higher risk of the composite outcomes of all-cause death and heart failure readmission than those
with an ACR <30 mg/dL. Our findings suggest that preoperative albuminuria can be a useful marker for predicting cardiac and renal
events after TAVR in daily practice.
[1] Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin 3rd JP, Gentile F,
et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American
Heart Association Joint Committee on clinical practice guidelines. Circulation.
2021;143:e72–e227.
[2] Lamprea-Montealegre JA, Shlipak MG, Estrella MM. Chronic kidney disease
detection, staging and treatment in cardiovascular disease prevention. Heart
2021.
[3] Yamamoto M, Hayashida K, Mouillet G, Hovasse T, Chevalier B, Oguri A,
et al. Prognostic value of chronic kidney disease after transcatheter aortic valve
implantation. J Am Coll Cardiol 2013;62:869–77.
[4] Dumonteil N, van der Boon RM, Tchetche D, Chieffo A, Van Mieghem NM,
Marcheix B, et al. Impact of preoperative chronic kidney disease on shortand long-term outcomes after transcatheter aortic valve implantation: a
Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus)
initiative substudy. Am Heart J 2013;165:752–60.
[5] Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The
definition, classification, and prognosis of chronic kidney disease: a KDIGO
controversies conference report. Kidney Int 2011;80:17–28.
[6] Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated
glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514–25.
[7] Turin TC, James M, Ravani P, Tonelli M, Manns BJ, Quinn R, et al. Proteinuria
and rate of change in kidney function in a community-based population. J Am
Soc Nephrol 2013;24:1661–7.
[8] Arnlov J, Nowak C. Association between albuminuria, incident cardiovascular
events, and mortality in persons without hypertension, diabetes, and cardiovascular disease. Eur J Prev Cardiol 2020.
[9] Adachi Y, Yamamoto M, Shimura T, Yamaguchi R, Kagase A, Tokuda T,
et al. Late kidney injury after transcatheter aortic valve replacement. Am Heart
J 2021;234:122–30.
[10] Phan DQ, Lee MS, Aharonian V, Mansukhani P, Moore N, Brar SS, et al. Association between mid-term worsening renal function and mortality after transcatheter aortic valve replacement in patients with chronic kidney disease.
Catheter Cardiovasc Interv 2020.
[11] Beohar N, Doshi D, Thourani V, Jensen H, Kodali S, Zhang F, et al. Association of transcatheter aortic valve replacement with 30-day renal function and
1-year outcomes among patients presenting with compromised baseline renal function: experience from the PARTNER 1 trial and registry. JAMA Cardiol
2017;2:742–9.
Acknowledgments
None.
Funding
None.
Disclosures
Hideki Ishii, Akihiko Usui, and Toyoaki Murohara are members
of Circulation Journal’s editorial team.
Hideki Ishii reports a relationship with Astellas Pharma Inc that
includes: speaking and lecture fees. Hideki Ishii reports a relationship with AstraZeneca that includes: speaking and lecture fees.
Hideki Ishii reports a relationship with Daiichi Sankyo Inc that
includes: speaking and lecture fees. Hideki Ishii reports a relationship with MSD that includes: speaking and lecture fees. Akihiko Usui reports a relationship with Terumo that includes: funding grants and speaking and lecture fees. Akihiko Usui reports a
relationship with Edwards Lifesciences Corporation that includes:
funding grants. Akihiko Usui reports a relationship with Senko
Medical Instrument Manufacturing Co Ltd that includes: funding
grants. Akihiko Usui reports a relationship with Medtronic that includes: funding grants. Akihiko Usui reports a relationship with
Lifeline that includes: funding grants. Toyoaki Murohara reports
a relationship with Bayer Pharmaceutical Co LTD that includes:
653
A. Tobe, A. Tanaka, Y. Tokuda et al.
Journal of Cardiology 79 (2022) 648–654
[12] Witberg G, Steinmetz T, Landes U, Pistiner Hanit R, Green H, Goldman S,
et al. Change in kidney function and 2-year mortality after transcatheter aortic
valve replacement. JAMA Netw Open 2021;4:e213296.
[13] Methven S, MacGregor MS, Traynor JP, Hair M, O’Reilly DS, Deighan CJ. Comparison of urinary albumin and urinary total protein as predictors of patient
outcomes in CKD. Am J Kidney Dis 2011;57:21–8.
[14] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis
2009;53:982–92.
[15] Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA,
et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation
2019;140:1569–77.
[16] Nerpin E, Ingelsson E, Riserus U, Sundstrom J, Larsson A, Jobs E, et al. The
combined contribution of albuminuria and glomerular filtration rate to the
prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant
2011;26:2820–7.
[17] Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin–
converting enzyme inhibitors and progression of nondiabetic renal disease. A
meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87.
[18] Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, et al. Renin angiotensin system blockade and cardiovascular outcomes
in patients with chronic kidney disease and proteinuria: a meta-analysis. Am
Heart J 2008;155:791–805.
[19] Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR,
et al. Cardiorenal protection with the newer antidiabetic agents in patients
with diabetes and chronic kidney disease: a scientific statement from the
American Heart Association. Circulation 2020;142:e265–ee86.
[20] Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF,
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med
2020;383:1436–46.
[21] Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of
finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J
Med 2020;383:2219–29.
[22] Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M,
Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int
2011;79:1331–40.
[23] Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH,
et al. Updated standardized endpoint definitions for transcatheter aortic valve
implantation: the valve academic research consortium-2 consensus document.
J Am Coll Cardiol 2012;60:1438–54.
654
...
論文の公開元へ
